Centessa Pharmaceuticals (CNTA) said late Thursday it priced an underwritten public offering of about 15.3 million American depositary shares at $14.75 per ADS for expected gross proceeds of about $225 million.
Each ADS represents one ordinary share. The offering was upsized from $150 million.
Underwriters have been granted a 30-day option to buy up to about 2.3 million additional ADSs.
The offering is set to close around Sept. 16.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。